Evidence map›Paper›PMID 28642620›Full record

ArticleLeukemia2017

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

P G Richardson, C C Hofmeister, N S Raje, D S Siegel, S Lonial, J Laubach, Y A Efebera, D H Vesole, A K Nooka, J Rosenblatt and 8 more

Erratum issued Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01497093 (A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01497093 phase1completednot on this map

A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)

TypeinterventionalSponsorCelgeneRan2012 to 2019Enrolled34ConditionsMultiple MyelomaArmsPomalidomide, Bortezomib, Dexamethasone
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Pathogenesis and treatment of multiple myeloma bone disease.The Japanese dental science review · 2021
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

P G RichardsonJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
C C HofmeisterDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
N S RajeMassachusetts General Hospital, Boston, MA, USA.
D S SiegelJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
S LonialDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
J LaubachJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Y A EfeberaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
D H VesoleJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
A K NookaDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
J RosenblattBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
D DossJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
M H ZakiCelgene Corporation, Summit, NJ, USA.
A BensmaineCelgene Corporation, Summit, NJ, USA.
J HerringCelgene Corporation, Summit, NJ, USA.
Y LiCelgene Corporation, Summit, NJ, USA.
L WatkinsCelgene Corporation, Summit, NJ, USA.
M S ChenCelgene Corporation, Summit, NJ, USA.
K C AndersonJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Dana-Farber Cancer Institute · USEmory University · USHackensack University Medical Center · USHarvard University · USThe Ohio State University · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4 mg days 1-14), bortezomib (1-1.3 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBortezomibDexamethasoneDrug Resistance, NeoplasmFemaleHumansLenalidomideMaleMaximum Tolerated DoseMiddle AgedMultiple MyelomaNeoplasm StagingProteasome InhibitorsBiomarkersBortezomibDexamethasoneLenalidomidepomalidomideProteasome InhibitorsThalidomide

Identifiers

PMID28642620
PMCPMC5729338
OpenAlexW2620717562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.